“The nonclinical safety of selumetinib has been evaluated in repeat dose oral toxicity studies of up to 3 months in rats and up to 26 weeks in mice and monkeys;”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Pivotal GLP studies
26-week mouse and monkey and 3-month rat oral repeat-dose studies
“The nonclinical safety of selumetinib has been evaluated in repeat dose oral toxicity studies of up to 3 months in rats and up to 26 weeks in mice and monkeys;”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Route in tox
Oral gavage
“Route of administration: Oral (gavage)”
✓ VerifiedFDA multi-discipline review, p. 66Source ↗